Medigene AG (0QGJ.L)

1.9150 0.0000 (0.00%) At close: 09:48AM BST

Medigene AG

Lochhamer Strasse 11
Planegg/Martinsried
Munich 82152
Germany
49 89 2000 330
https://www.medigene.com

Sector(s): 
Industry: 
Full-time employees: 61

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Dolores J. Schendel	Chief Scientific Officer, Member of Exec. Management Board and Head of R&D	375k	N/A	N/A
Dr. Selwyn Ho MB BS, MBBS	CEO & Member of Exec. Management Board	N/A	N/A	1971
Dr. Ernst-Ludwig Winnacker	Co-Founder & Chairman Scientific Advisory Board	N/A	N/A	1941
Dr. Birger Kohlert	Chief Financial Officer	N/A	N/A	N/A
Dr. Anna Niedl	VP Investor Relations & Corp. Communications	N/A	N/A	N/A
Dr. Rene Goedkoop	Acting Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.

Corporate governance

Medigene AG’s ISS governance QualityScore as of 1 October 2022 is 3. The pillar scores are Audit: 7; Board: 3; Shareholder rights: 1; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.